5 unknown. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 5 |
| Phase 2 | 1 | Unknown 1 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy TQB3909 tablets, TQB3702 tablets - Hematologic Malignancy | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 208 | 2024-01-01 | 2024-01-18 |
| A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML BC3402 Injection - Hematologic Malignancy | Phase 1 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 13 | 2023-07-06 | 2023-07-24 |
| Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule Ivaltinostat, Placebo - Hematologic Malignancy, Solid Tumor | Phase 1 | Unknown | Machaon Biotherapeutics, Inc. | 32 | 2023-03-09 | 2023-10-23 |
| Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects TQB3702 tablets - Hematologic Malignancy | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 137 | 2022-11-01 | 2022-11-09 |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation - Hematologic Malignancy | Phase 1 / Phase 2 | Unknown | Sichuan University | 56 | 2022-03-01 | 2022-03-15 |
Hematologic Neoplasms (5) · Fibrosis (1) · Recurrence (1)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1)
N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide (1)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Biocity Biopharmaceutics Co., Ltd. (1) · Machaon Biotherapeutics, Inc. (1) · Sichuan University (1)
China (4) · South Korea (1)
Jie Ji, MD (1)